Antibody-Mediated Effector Function: Learning and Challenges from Early Discovery to Development

Payal Mehta, PhD Research Scientist Eli Lilly & Company CaSSS Bioassay Conference, Silver Spring, MD 9<sup>th</sup> May 2017





- Overview of Antibody (Ab)-Mediated Effector Function
- Ab-Effector Function Testing During Life Cycle Development of Drug
- Transition Challenges from Discovery to Development
  - Mouse to Human transition
  - Choice of Appropriate Assay Format When Multiple Receptors Are Part of MOA
  - Finding Appropriate Target Cell Lines
    - Representative of Physiological Target Expression
    - Stability Over Assay Runs
- Summary

## **Bimodal Nature of Antibodies: Implications for Safety and Efficacy**





Table 1 Key features of the four IgG isotypes					
	lgG1	lgG2	lgG3	lgG4	
FcRn <sup>e</sup>	+	+	+	+	
Effector functions					
C1 <sup>e</sup>	++	_	+++	_	
FcgRI <sup>e</sup>	+++	_	+++	++	
FcgRII <sup>e</sup>	+	±	+	?	
FcgRIIIa/b <sup>e</sup>	+	_	+	±	

Eli Lilly & Company

Salfeld et al, Nature Biotech (2007) <sup>3</sup>

## Is Effector Function Always Non-Desirable?



- Beneficial where target cell depletion is NOT desired- Ex. autoimmunity targets, immuno-oncology targets
- Fc-engineering of antibody to ablate
  effector function

- Beneficial where target cell depletion is desired MOA
- Fc-engineering of antibody to enhance
  effector function


## **Effector Function Potential: Interplay with** MOA

#### OPINION

#### Advances in the assessment and control of the effector functions of therapeutic antibodies

Xu-Rong Jiang, An Song, Svetlana Bergelson, Thomas Arroll, Bhavin Parekh, Kimberly May, Shan Chung, Robert Strouse, Anthony Mire-Sluis and Mark Schenerman


#### Nature Reviews Drug Discovery, 2011 (10), 101




## Effector Function Testing: Continuous Monitoring

Effector Function Status is impacted by isotype, Fc engineering or Glyco-engineering

Jian et al; Nature Reviews Drug Discovery, 2011 (10), 101




## Transitioning Effector Function Cellular Assays from Discovery to Development




## Case Study #1: Transitioning Effector Function Data from Mouse to Human

- Understanding of putative MOA of therapeutic antibody within the context of a disease comes from *in vivo* mouse studies
  - Mouse and human FcγR repertoire is very different
  - Mouse IgG isotypes different than humans
  - Human and mouse FcγR (s) exhibit differences in IgG binding pattern's
  - Human and mouse FcγR (s) differ in lineage expression profiles
  - Reporter cell-based assays use cell lines expressing individual FcγR's


These differences add to the complexity of crossing over experimental data between the two species




Advances in Bioscience and Biotechnology, Vol.4 No.4A(2013)



## Transitioning *in vivo* Results to Design Cell-based Effector Function Assays






- Effector function independent trans-co engagement of agonist CD40 Ab with FcγRIIb is MOA.
- PD-L1 blocking antibody requires trans engagement with activating receptor for optimal *in vivo* efficacy.
- On the contrary interaction with FcγR's reduces efficacy of PD-1 blocking antibody in *in vivo* mouse tumor models.
- Therefore, choice of backbone is dictated by a better understanding of MOA of antibody and a thorough understanding of biology (QoD)

Using mice surrogate antibody data to understand relevant human  $Fc\gamma R$ -engagement and its link to MOA is a challenge


## Case Study #2: Choosing a Reporter Assay When Multiple FcγR's Are Involved in MOA

#### **Evidence for FcyRIIIa**




#### Herter S, et al, J Immunol 2014; 192:2252-2260


#### **Evidence for FcyRlla**




#### Richard et al, Mol Cancer Ther 2008;7(8). August 2008)




## Should QC Assay be Selected Based on Its **Ability to Monitor CQA?**




## Case Study # 3: Choosing an Appropriate Target Cell Line with Endogenous Receptor Expression






- None of the IgG-fusion constructs gave a response in FcγRIIIa activity assays.
- Is it the Cell Line issue? Expression issue?


# Selecting a Target Cell Line with a Second Positive Marker for Effector Function



- The Biological function of the receptor was confirmed via Signaling experiments on the new Target Cell Line.
- If IgG1-Fc functionality does not respond in the FcγRIIIa activity assays do we need to confirm this with multiple target cell lines?
- However, it is not always easy to find cell lines with physiologically relevant target expression 5/25/2017




## Providing an Appropriate Context When Choosing An Overexpression Target Cell Line



- Data with overexpression systems tend to be exaggerated and may not be representative of true physiological scenario's.
- It is important to put the data obtained within appropriate context.
- Clinical data from and knowledge from previous efforts may be helpful in this regard.



Overexpressed Antigen





- Effector function is a critical component of life cycle management of therapeutic Mab. It is reflective of
  - Therapeutic Efficacy
  - Safety/risk
  - Lot to Lot variation (CQA)
- The goals of discovery work on ab-mediated effector function testing is very different than development work
- Transition Challenges include
  - Mouse to human transition
  - Multiple receptors involved in MOA
  - Finding suitable target cell lines with physiologically relevant cell lines
- It is important to integrate the knowledge of FcγR-MOA into an appropriate cell-based assay as early as possible and use previously available clinical data to drive testing some of the molecules

## **Acknowledgments**

### Eli Lilly & Company

Derrick Witcher Bhavin Parekh Robert Benschop Uma Kuchibhotla